TALVEYHCP.COM: Keyword Density Checker

Total words: 1920 | 2-word phrases: 496 | 3-word phrases: 545 | 4-word phrases: 567

PAGE INFO

Title	Try to keep the title under 60 characters (54 characters) Official HCP Website \| TALVEY® (talquetamab-tgvs) HCP
Description	Try to keep the meta description between 50 - 160 characters (143 characters) View the official healthcare professional (HCP) website for TALVEY® (talquetamab-tgvs). See Full Prescribing, Safety Info & Boxed Warning.
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	No H1 tag on the page (0 characters)

#	Keyword	Frequency	Density
1	janssen biotech inc	5	0.92%
2	tcell redirection therapy	4	0.73%
3	dosing 95 ci	3	0.55%
4	to tcell redirection	3	0.55%
5	relapsed or refractory	3	0.55%
6	for healthcare professionals	2	0.37%
7	united states and	2	0.37%
8	qw dosing 95	2	0.37%
9	exposed to tcell	2	0.37%
10	anticd38 monoclonal antibody	2	0.37%
11	and puerto rico	2	0.37%
12	states and puerto	2	0.37%
13	immunomodulatory agent and	2	0.37%
14	the united states	2	0.37%
15	orr† with qw	2	0.37%
16	an immunomodulatory agent	2	0.37%
17	prior lines of	2	0.37%
18	biotech inc 2024	2	0.37%
19	for the treatment	2	0.37%
20	the treatment of	2	0.37%
21	included patients who	2	0.37%
22	with qw dosing	2	0.37%
23	this site is	2	0.37%
24	with relapsed or	2	0.37%
25	get in touch	2	0.37%
26	or refractory multiple	2	0.37%
27	refractory multiple myeloma	2	0.37%
28	complete response vgpr	1	0.18%
29	imwg international myeloma	1	0.18%
30	evaluation and mitigation	1	0.18%

#	Keyword	Frequency	Density
1	to tcell redirection therapy	3	0.53%
2	or refractory multiple myeloma	2	0.35%
3	the united states and	2	0.35%
4	states and puerto rico	2	0.35%
5	qw dosing 95 ci	2	0.35%
6	with qw dosing 95	2	0.35%
7	orr† with qw dosing	2	0.35%
8	janssen biotech inc 2024	2	0.35%
9	with relapsed or refractory	2	0.35%
10	for the treatment of	2	0.35%
11	relapsed or refractory multiple	2	0.35%
12	an immunomodulatory agent and	2	0.35%
13	united states and puerto	2	0.35%
14	inhibitor an immunomodulatory agent	1	0.18%
15	proteasome inhibitor an immunomodulatory	1	0.18%
16	a proteasome inhibitor an	1	0.18%
17	anticd38 monoclonal antibody efficacy	1	0.18%
18	monoclonal antibody efficacy was	1	0.18%
19	including a proteasome inhibitor	1	0.18%
20	accessed april 26 2024	1	0.18%
21	≥3 prior systemic therapies	1	0.18%
22	received ≥3 prior systemic	1	0.18%
23	antibody efficacy was based	1	0.18%
24	efficacy was based on	1	0.18%
25	had received ≥3 prior	1	0.18%
26	footer links content fetched	1	0.18%
27	was based on orr	1	0.18%
28	redirection therapy refers to	1	0.18%
29	in participants with relapsed	1	0.18%
30	participants with relapsed or	1	0.18%
31	multiple myeloma clinicaltrialsgov identifier	1	0.18%
32	myeloma clinicaltrialsgov identifier nct04634552	1	0.18%
33	clinicaltrialsgov identifier nct04634552 updated	1	0.18%
34	both cart and bispecific	1	0.18%
35	to both cart and	1	0.18%
36	refers to both cart	1	0.18%
37	therapy refers to both	1	0.18%
38	tcell redirection therapy refers	1	0.18%
39	based on orr and	1	0.18%
40	irc using imwg criteria134§	1	0.18%

#	URL	Whois	Check
1	https://www.talvey.com/	Whois	talvey.com
2	https://www.talvey.com/	Whois	talvey.com
3	https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TALVEY-pi.pdf	Whois	janssenlabels.com
4	https://www.tec-talrems.com/	Whois	tec-talrems.com
5	https://www.immunotherapy4myeloma.com/	Whois	immunotherapy4myeloma.com
6	https://www.janssen.com/fda-approves-talveytm-talquetamab-tgvs-first-class-bispecific-therapy-treatment-patients-heavily	Whois	janssen.com
7	https://www.janssenscience.com/	Whois	janssenscience.com
8	https://www.janssen.com/oncology	Whois	janssen.com